Novo Nordisk is expected to find out in October whether FDA will approve its long-acting insulin Tresiba for sale in the US market. However, if approved, Tresiba faces growing competition from Sanofi, which markets the leading basal insulin Lantus along with Toujeo.
A Medicare reimbursement policy proposing that multiple biosimilars have the same pricing J-code for Medicare reimbursement purposes could ultimately result in fewer treatment options, according to a group representing the industry.
We asked the Managed Healthcare Executive editorial advisory board, what book would you recommend to other executives? Here's what they said.
Experts say the benefits of ICD-10 will far outweigh the risks. Here's why.
Although many states and the federal government are taking a close look at granting provider status for pharmacists, the two entities have slightly different priorities.
As healthcare systems move toward new payment and delivery models, physicians are the key to success.
G. William Hoagland, senior vice president of the Bipartisan Policy Center, believes that the Affordable Care Act and possible repeals toward it will be issues in the 2016 election.
Surprisingly, giving prescriptions to the wrong patients is still common in community pharmacies across the U.S. According to the Institute for Safe Medication Practices (ISMP), this error occurs about once in every 1,000 prescriptions dispensed.
FDA has approved azelaic acid (Finacea, Bayer HealthCare) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
Pharmaceutical firms “underinvest” in long-term research to develop new cancer-fighting drugs because of the time and expense, according to a new study.
FDA approved epilepsy drug levetiracetam (Spritam), the first FDA-approved drug that utilizes three-dimensional printing (3DP).
Unichem Pharmaceuticals issued a voluntary recall of Hydrochlorothiazide Tablets 25 mg, 1,000-count bottle. The precautionary measure is due to the identification of a Clopidogrel tablet found in a bottle at one pharmacy.
Global sales of pharmaceuticals will soar to $1.3 trillion in 2018, led by new cancer and specialty drug introductions, a new report found.
FDA is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS).
More Medicaid incentive programs are cropping up across the country. Here's a look at the programs, and some of the early results.
The Medicaid Incentives for Prevention of Chronic Diseases initiative, funded by the Department of Health and Human Services, is the biggest thing going in Medicaid wellness programs right now.
Drug and device makers are taking into account the health plans’ perspectives in the commercialization of their products, according to a new survey.
After positive phase 3 trial data for its treatment for the bleeding disorder von Willebrand disease, Baxalta Inc. is awaiting FDA approval for the drug.
Experts weigh in on what to expect as provisions of the Medicare Access and CHIP Reauthorization Act roll out.
Technology that passes the non-techie empowerment test can empower your employees. Passing the test requires answering "yes" to these two simple questions.
As the healthcare system undergoes rapid change, there are three important trends that managed care executives should keep an eye on.
Here are some innovative ways EHR vendors are working to expand interoperability for providers and payers
There are advocates who say Medicare needs to increase the type of coverage it provides for beneficiaries.
Diabetes costs $322 billion per year in the U.S. Help empower consumers for a healthier bottom line.
On the 50th anniversary of Medicare, a look at the program's past, present, and future.
We want to know what you think about the top challenges facing the industry. Please take our quick survey. You’ll be entered to win a $200 Visa gift card.
FDA has granted priority review to naloxone nasal spray (Indivior) for the treatment of opioid overdose. If approved, naloxone nasal spray is expected to be the first FDA-approved intranasal naloxone product indicated to treat opioid overdose in the United States.
There have been 8 high-profile FDA approvals in the last few weeks. Here is an overview.
Healthcare spending growth faster than recent trends.
As a healthcare executive, leading your organization through today’s rapidly changing business environment means tackling serious issues. Here's how to do it right.
